Showing 201 - 220 results of 115,186 for search '(( a non decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.54s Refine Results
  1. 201
  2. 202

    <i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

    Published 2017
    “…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”
  3. 203
  4. 204
  5. 205

    Image_5_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif by Wan Fu (3681799)

    Published 2021
    “…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”
  6. 206

    Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice by Michael T Buckley (37161)

    Published 2011
    “…All bladders were voided of urine prior to weighing. Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. , Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). , Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).…”
  7. 207
  8. 208
  9. 209

    mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

    Published 2019
    “…<p>(<b>A–B</b>) Bath perfusion of DHPG for 3 min reduced GlyR-IPSCs (<b>A</b>; 70.2 ± 4.2% of baseline at 15–20 min post-DHPG, <i>t</i>[16] = 6.707, <i>p</i> < 0.001, paired Student <i>t</i> test), but not GABA<sub>A</sub>-receptor–mediated IPSCs (<b>B</b>; 102.9 ± 3.3% of baseline at 15–20 min post-DHPG, <i>t</i>[5] = 0.347, <i>p</i> = 0.743) in spinal slices of mice. …”
  10. 210
  11. 211
  12. 212
  13. 213
  14. 214

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  15. 215

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
  16. 216
  17. 217

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”
  18. 218
  19. 219
  20. 220

    Proteasome activity was decreased in the <i>myc-rpt6-S119A</i> mutant. by Esther Magdalena Marquez-Lona (4183126)

    Published 2017
    “…<p>(A) Lysates from strains in stationary phase (A<sub>600</sub>>5.0) were subjected to native gel electrophoresis followed by an in-gel activity assay with the fluorogenic proteasome substrate Suc-LLVY-AMC. …”